Don’t Call It A Center Of Excellence: Accelerating Rare Disease Cures Program Launched By CDER
Executive Summary
‘Umbrella’ program is intended to ensure all rare disease and related programs at CDER are working together, which seems similar to the rare disease center of excellence concept that stakeholders want to coordinate activities across the FDA.
You may also be interested in...
Push To Create Ultra-Rare Orphan Drug Designation Finds Resistance At US FDA
Agency officials don’t think a new definition or incentives will fix the issues related to development in rare diseases with only a handful of patients, as advocates continue pushing the idea.
Rare Diseases: European Market Access ‘Better Organized’ Than US, Says Rhythm
Rhythm is working with country-level authorities and centers of excellence in Europe to gain reimbursement and access for its obesity treatment Imcivree.
Supplemental Filings: CBER/CDER Real-Time Comms, DCT Fall Off, Mifepristone REMS
US CBER director Peter Marks suggests CDER could join its real-time communications pilot program, CDER's Jacqueline Corrigan-Curay says the use of decentralized trials has declined since the pandemic eased, and the GAO concludes that revisions to the mifepristone REMS do not require congressional review.